Table 4.

Characteristics of patients with late toxicities of >Grade 3

Number	Grade	Age (years)	Primary site	Late toxicities	Onset (months)	Outcome	Cause of death	Chemotherapy regimen	Radiation dose (Gy)	Initial field length (cm)	Boost field length (cm)
1	5	70	Mt–Lt	Sudden death	150	Died without relapse	Sudden death	CDDP + 5-FU continuous infusion	50	22	9.0
2	5	67	Ut–Mt	Secondary malignancy	77	Died with secondary malignancy	AML	CDDP + 5-FU	60	24	18.0
	3			Pleural effusion	35
3	4	73	Ut–Mt	Cardiac ischemia	57	Died without relapse	ARDS	CDDP + 5-FU continuous infusion	60	24	12.1
	3			Pleural effusion	40
	3			Pericardial effusion	40
4	3	74	Mt	Cardiac ischemia	151	Died with lung cancer (out of field)	Lung cancer	CDDP + 5-FU continuous infusion	55	26	19.8
5	3	58	Lt	Pleural effusion	22	Died with relapse	Esophageal cancer	CDDP + 5-FU	60	29	20.6
	3			Pericardial effusion	22
6	3	74	Ut–Mt	Pleural effusion	20	Died without relapse	Infectious pneumonitis	CDDP + 5-FU	64	21.5	10.0
7	3	80	Ut–Mt	Pleural effusion	19	Died with relapse	Esophageal cancer	CDDP + 5-FU	60	24	11.3
8	3	71	Mt	Pleural effusion	19	Died with relapse	Esophageal cancer	CDDP + 5-FU continuous infusion	60	27.1	14.0
	3			Pericardial effusion	19
9	3	68	Mt–Lt	Pleural effusion	14	Died with relapse	Esophageal cancer	CDDP + 5-FU	60	28.2	20.2
10	3	81	Lt	Pleural effusion	13	Alive without relapse		S-1	54	21	10.0
	3			Pericardial effusion	13
11	3	59	Ut	Radiation pneumonitis	10	Died with relapse	Esophageal cancer	CDDP + 5-FU	60	25	15.6

AML = acute myeloid leukemia; Ut = upper third of thoracic esophagus; Mt = middle third of thoracic esophagus; Lt = lower third of thoracic esophagus; CDDP = cisplatin; 5-FU = 5-fluorouracil; S-1 = TS-1; tegafur, gimeracil, oteracil potassium.